Eagle Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EAGLE PHARMS, and when can generic versions of EAGLE PHARMS drugs launch?
EAGLE PHARMS has six approved drugs.
There are twenty-five US patents protecting EAGLE PHARMS drugs.
There are one hundred and twenty patent family members on EAGLE PHARMS drugs in thirty-three countries and two supplementary protection certificates in two countries.
Summary for Eagle Pharms
| International Patents: | 120 |
| US Patents: | 25 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 6 |
Drugs and US Patents for Eagle Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | 9,597,399 | See Plans and Pricing | See Plans and Pricing | ||||
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | 10,052,385 | See Plans and Pricing | See Plans and Pricing | ||||
| Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | 8,110,225 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Eagle Pharms | BELRAPZO | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 205580-001 | May 15, 2018 | RX | Yes | Yes | 11,103,483 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | 9,597,397 | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for EAGLE PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 100 mg/4 mL (25 mg/mL) multiple-dose vials | ➤ Subscribe | 2017-05-04 |
International Patents for Eagle Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 101119708 | See Plans and Pricing |
| Lithuania | 2528602 | See Plans and Pricing |
| Canada | 2593582 | See Plans and Pricing |
| Croatia | P20161771 | See Plans and Pricing |
| Japan | 6133943 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eagle Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0432677 | SPC/GB05/011 | United Kingdom | See Plans and Pricing | PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920 |
| 0432677 | 7/2005 | Austria | See Plans and Pricing | PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
